At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 212 enrolled
Drug / intervention
PF-06700841 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06700841 IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
In Brief
A Phase 2 clinical trial evaluating PF-06700841 and Placebo for Chronic Plaque Psoriasis. Completed, enrolled 212 participants across 44 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque Psoriasis
CountriesCanada, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartDec 2016
Primary CompletionMar 2018
TodayJul 2026
First PostedNov 21, 2016
Enrollment StartDec 1, 2016
Primary CompletionMar 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.6 years ago
Interventions
PF-06700841drug
Placeboother